Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Malignant Melanoma

Free Subscription Articles published in Cancer Retrieve available abstracts of 57 articles: HTML format Text format

Single Articles

March 2010
1. PEREZ-GOMEZ B , Aragones N, Pollan M
   Divergent cancer pathways for early onset and late onset cutaneous malignant melanoma: a role for sex-site interaction.
   Cancer. 2010.
   PubMed     Text format     Related articles   
   
   
   
2. ANDERSON WF , Tucker MA, Rosenberg PS
   Reply to Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma.
   Cancer. 2010.
   PubMed     Text format     Related articles   
   
   
   
3. MOUGIAKAKOS D , Johansson CC, Trocme E, All-Ericsson C, et al
   Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.
   Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. MORENO MA , Roberts DB, Kupferman ME, Demonte F, et al
   Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center.
   Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   February 2010
5. XING Y , Chang GJ, Hu CY, Askew RL, et al
   Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis.
   Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. KASHANI-SABET M
   Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction.
   Cancer. 2010.
   PubMed     Text format     Related articles   
   
   
   
7. HINO R , Kabashima K, Kato Y, Yagi H, et al
   Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
   Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. KU GY , Yuan J, Page DB, Schroeder SE, et al
   Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
   Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
9. BHATT RS , Merchan J, Parker R, Wu HK, et al
   A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
   Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. HERSEY P , Sosman J, O'Day S, Richards J, et al
    A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), +/- dacarbazine in patients with stage IV metastatic melanoma.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. MAYS MP , Martin RC, Burton A, Ginter B, et al
    Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. MESSINA JL , Sondak VK
    Refining the criteria for sentinel lymph node biopsy in patients with thinner melanoma: a roadmap for the future.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
13. VYAS A , Avritscher R, Ensor J, Ross M, et al
    Isolated limb infusion with cytotoxic agents: a simplified approach for venous access.
    Cancer. 2010;116:459-64.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. PASQUALI S , Mocellin S, Campana LG, Bonandini E, et al
    Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases : personal Experience and Literature Meta-Analysis.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. BYRD DR
    The persistent anchor of lymph node removal in patients with melanoma.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
16. URSO C
    The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution.
    Cancer. 2010;116:258.
    PubMed     Text format     Related articles   
    
    
    November 2009
17. BRAUER JA , Wriston CC, Troxel AB, Elenitsas R, et al
    Characteristics associated with early and late melanoma metastases.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. CLARK JI , Moon J, Hutchins LF, Sosman JA, et al
    Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
19. HERSH EM , O'Day SJ, Ribas A, Samlowski WE, et al
    A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. EISEN T , Trefzer U, Hamilton A, Hersey P, et al
    Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. GAJDOS C , Griffith KA, Wong SL, Johnson TM, et al
    Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
22. GLASPY J , Atkins MB, Richards JM, Agarwala SS, et al
    Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
23. AGRAWAL S , Kane JM 3rd, Guadagnolo BA, Kraybill WG, et al
    The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. MURALI R , Cochran AJ, Cook MG, Hillman JD, et al
    Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
25. BEASLEY GM , McMahon N, Sanders G, Augustine CK, et al
    A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. MARTIN RC , Murali R, Scolyer RA, Fitzgerald P, et al
    So-called "malignant blue nevus": a clinicopathologic study of 23 patients.
    Cancer. 2009;115:2949-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
27. WEBER JS , Zarour H, Redman B, Trefzer U, et al
    Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. ANDERSON WF , Pfeiffer RM, Tucker MA, Rosenberg PS, et al
    Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
29. RIBER-HANSEN R , Nyengaard JR, Hamilton-Dutoit SJ, Steiniche T, et al
    Stage migration after minor changes in histologic estimation of tumor burden in sentinel lymph nodes: the protocol trap.
    Cancer. 2009;115:2177-87.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
30. MANDELIN J , Lin EC, Hu DD, Knowles SK, et al
    Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin.
    Cancer. 2009;115:1753-64.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
31. XING Y , Badgwell BD, Ross MI, Gershenwald JE, et al
    Lymph node ratio predicts disease-specific survival in melanoma patients.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. SPILLANE AJ , Winstanley J, Thompson JF
    Lymph node ratio in melanoma : a marker of variation in surgical quality?
    Cancer. 2009.
    PubMed     Text format     Related articles   
    
    
    
33. KROON HM , Lin DY, Kam PC, Thompson JF, et al
    Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
34. GELLER AC , Elwood M, Swetter SM, Brooks DR, et al
    Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. LUDGATE MW , Fullen DR, Lee J, Lowe L, et al
    The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution.
    Cancer. 2009;115:631-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
36. POZDNYAKOVA O , Grossman J, Barbagallo B, Lyle S, et al
    The hair follicle barrier to involvement by malignant melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. TARHINI AA , Millward M, Mainwaring P, Kefford R, et al
    A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. TANDLE A , Hanna E, Lorang D, Hajitou A, et al
    Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.
    Cancer. 2009;115:128-39.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
39. WARYCHA MA , Zakrzewski J, Ni Q, Shapiro RL, et al
    Meta-analysis of sentinel lymph node positivity in thin melanoma (</=1 mm).
    Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. PEREZ DG , Suman VJ, Fitch TR, Amatruda T 3rd, et al
    Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
    Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
41. WARYCHA MA , Christos PJ, Mazumdar M, Darvishian F, et al
    Changes in the presentation of nodular and superficial spreading melanomas over 35 years.
    Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
42. CHEN JY , Hruby G, Scolyer RA, Murali R, et al
    Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases.
    Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. MOCELLIN S , Nitti D
    Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis.
    Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. DEMIERRE MF , Sabel MS, Margolin KA, Daud AI, et al
    State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.
    Cancer. 2008;113.
    PubMed     Text format     Related articles   
    
    
    
45. ATKINS MB , Sosman JA, Agarwala S, Logan T, et al
    Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
    Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
46. TARHINI AA , Kirkwood JM, Gooding WE, Moschos S, et al
    A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
    Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
47. HAUSCHILD A , Dummer R, Ugurel S, Kaehler KC, et al
    Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
    Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2008
48. CORMIER JN , Ross MI, Gershenwald JE, Lee JE, et al
    Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of Cancer Therapy-Melanoma questionnaire.
    Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. ANAYA DA , Xing Y, Feng L, Huang X, et al
    Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.
    Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2008
50. LASITHIOTAKIS K , Leiter U, Meier F, Eigentler T, et al
    Age and gender are significant independent predictors of survival in primary cutaneous melanoma.
    Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. CANOVAS D , Rennie IG, Nichols CE, Sisley K, et al
    Local environmental influences on uveal melanoma: vitreous humor promotes uveal melanoma invasion, whereas the aqueous can be inhibitory.
    Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. TARHINI AA , Kirkwood JM, Tawbi H, Gooding WE, et al
    Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.
    Cancer. 2008;112:1131-1138.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. MENDENHALL WM , Amdur RJ, Grobmyer SR, George TJ Jr, et al
    Adjuvant radiotherapy for cutaneous melanoma.
    Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
54. PIAO Y , Guo M, Gong Y
    Diagnostic challenges of metastatic spindle cell melanoma on fine-needle aspiration specimens.
    Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2008
55. HAUSCHILD A , Gogas H, Tarhini A, Middleton MR, et al
    Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
    Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. PLAZA JA , Perez-Montiel D, Mayerson J, Morrison C, et al
    Metastases to soft tissue: a review of 118 cases over a 30-year period.
    Cancer. 2008;112:193-203.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2007
57. EINSPAHR JG , Thomas TL, Saboda K, Nickolof BJ, et al
    Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
    Cancer. 2007;.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: